ScreenerHero

OBIOOrchestra BioMed Holdings Inc. Ordinary Shares

NAS · US · Healthcare · Biotechnology · orchestrabiomed.com
5.360USD-3.42%Mkt Cap: 322.16M $P/E: —

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap322.16M $
Enterprise Value297.26M $
Revenue (TTM)31.98M $
Gross Profit33.29M $
Net Income (TTM)-52.70M $
Revenue/Share0.5370 USD
Last Price5.360 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees86
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.58
PEG—
EV/EBITDA-5.16
EV/Revenue9.30
P/S10.21
P/B16.92
EPS (TTM)-0.82
EPS (Forward)-1.52
52W Range
2.20089% of range5.770
52W High5.770 USD
52W Low2.200 USD
Profitability
Gross Margin99.43%
Oper. Margin-25404.55%
EBITDA Margin-180.27%
Profit Margin-157.40%
ROE-98.38%
ROA-45.88%
Growth
Revenue Growth-89.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-48.96M $
CapEx (TTM)489.00K $
FCF Margin-99.49%
FCF Yield-9.87%
Net Debt-39.20M $
Net Debt/EBITDA0.68
Balance Sheet
Debt/Equity0.30
Current Ratio8.26
Quick Ratio8.17
Book Value/Sh0.3210 USD
Cash/Share1.830 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.33 USD
Upside (mean)+130.1%
Target Range9.000 USD – 20.00 USD
$9.000+130.1% to mean$20.00
# Analysts6
Ownership
Shares Out.60.11M
Float32.95M
Insiders24.47%
Institutions47.20%
Short Interest
Short Ratio11.0d
Short % Float6.55%
Short % Out.4.04%
Shares Short2.43M
Short (prev mo.)2.22M
Technical
SMA 504.129 (+29.8%)
SMA 2004.213 (+27.2%)
Beta0.50
S&P 52W Chg18.16%
Avg Vol (30d)203.72K
Avg Vol (10d)415.15K
Technical Indicators
RSI (14)75.4
MACD0.2983
MACD Signal0.1650
MACD Hist.+0.1333
BB Upper5.267 USD
BB Middle4.280 USD
BB Lower3.293 USD
BB Width46.12%
ATR (14)0.2749 USD
Vol Ratio (20d)1.41x